Previous 10 | Next 10 |
VBL Therapeutics (NASDAQ: VBLT ) announces new data on its proprietary anti-MOSPD2 antibodies in rheumatoid arthritis (RA). The results are being virtually presented at EULAR. More news on: Vascular Biogenics Ltd., Healthcare stocks news, Stocks on the move, Read more ...
TEL AVIV, Israel, June 04, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), (the “Company”) today announced new data implicating the potential of its proprietary anti-MOSPD2 antibodies for treatment of rheumatoid arthritis (RA). VBL's study entitled “MO...
OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion of an absolute percentage advantage of 10% or higher in CA-125 response in the VB-111 treated arm compared to control. The DSMC recom...
TEL AVIV, Israel, May 18, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) announced today that new data suggesting the potential of its proprietary bi-specific antibodies for immune-mediated targeting of solid tumors will be presented at the Annual American Association for Cancer...
Vascular Biogenics Ltd. (VBLT) Q1 2020 Earnings Conference Call May 14, 2020 08:30 AM ET Company Participants Michael Wood - Investor Relations, LifeSci Advisors Dror Harats - Chief Executive Officer Amos Ron - Chief Financial Officer Conference Call Participants Jonathan A...
VBL Therapeutics (NASDAQ: VBLT ): Q1 GAAP EPS of -$0.15 beats by $0.02 . More news on: Vascular Biogenics Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
TEL AVIV, Israel, May 14, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the first quarter ended March 31, 2020, and provided a corporate update. “We reached an important milestone in our development of VB-111 in ovarian cancer with ...
TEL AVIV, Israel, May 13, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced offering of 5,142,857 ordinary shares of the Company, at a purchase price of $1.575 per share, in a registered direct offering priced at-the-m...
VBL Therapeutics (NASDAQ: VBLT ) has closed its previous registered direct offering of 6,349,208 ordinary shares at a purchase price of $1.575/share and unregistered warrants to purchase same number of ordinary shares, for gross proceeds of ~$10M. More news on: Vascular Biogenics Lt...
TEL AVIV, Israel, May 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced registered direct offering of 6,349,208 ordinary shares of the Company, at a purchase price of $1.575 per share, in a registered direct offeri...
News, Short Squeeze, Breakout and More Instantly...
Vascular Biogenics Ltd. Company Name:
VBLT Stock Symbol:
NASDAQ Market:
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GL...
MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annua...
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today ann...